Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
NCT ID: NCT04576858
Last Updated: 2020-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1950 participants
OBSERVATIONAL
2020-02-03
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Surgical resection + perioperative chemotherapy (cohort 1)
* Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2)
* Definitive chemoradiotherapy with curative intent (cohort 3)
* Systemic therapy with the intent to prolong survival (cohort 4)
* Palliative treatment without the use of chemotherapy (cohort 5)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer
NCT04530890
Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer
NCT05356585
Detection of Tumor DNA in Blood Samples From Cancer Patients
NCT02288754
ctDNA Screening in Advanced HER2 Positive Gastric Cancer
NCT04520295
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
NCT06589388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Surgical resection + perioperative chemotherapy
Circulating tumor DNA
Measurement of circulating tumor DNA from plasma over a period of 2 years.
Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery
Circulating tumor DNA
Measurement of circulating tumor DNA from plasma over a period of 2 years.
Cohort 3: Definitive chemoradiotherapy
Circulating tumor DNA
Measurement of circulating tumor DNA from plasma over a period of 2 years.
Cohort 4: Chemotherapy with the aim to prolong life expectancy
Circulating tumor DNA
Measurement of circulating tumor DNA from plasma over a period of 2 years.
Cohort 5: Non-chemotherapeutic palliation
E.g. Palliative radiotherapy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Circulating tumor DNA
Measurement of circulating tumor DNA from plasma over a period of 2 years.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Mau-Sørensen
Chief Physician, MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CURE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.